genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Grail
GEN Edge
StockWatch: “Final Resolution” Set for Illumina’s Grail Saga
GEN Edge
JPM: Illumina’s New CEO Spells Out 2024 Priorities, Presents Preliminary Q4, 2023 Results
GEN Edge
StockWatch: Illumina Shares Climb Back after Tailspin from Q3 Results
News
Illumina to Divest of Grail after Appeals Court Defeat
Industry News
Illumina Links Grail Divestiture to Losing European Or U.S. Appeals
Industry News
European Commission Orders Illumina to Divest of Grail
GEN Edge
StockWatch: Illumina Results Leave Investors, Analysts Anxious
News
Illumina Vows Appeal of $479M Fine for Acquiring Grail before EC Approval
Drug Discovery
StockWatch: FTC vs. Amgen-Horizon Could Slam Brakes on Biotech M&A
Cancer
AACR News: GRAIL Validates Methylation-Based Cancer Detection Test
1
2
Page 1 of 2
Scroll Up
Scroll Up
